Peptide therapy and FDA approval: what wellness TikTok gets right and wrong

What did @dr.sheila_derm actually say?

She called the normalization of injectable peptides a "scam" and stated that "most of those injectable peptides that wellness influencers are on are for research purposes only, not for human use." That's the core argument: these compounds lack FDA approval for routine clinical use in humans, and therefore marketing them as wellness tools is misleading at best.

To be fair, she kept it short. There were no dosing recommendations, no disease cure claims, and no specific product endorsements. The message was essentially regulatory: these are research chemicals being sold to consumers as health interventions. That framing, while blunt, is not without basis.

Does the science back this up?

On the regulatory facts, she's largely correct. Where it gets more complicated is the implied conclusion that lack of FDA approval equals zero legitimate use.

BPC-157, TB-500, CJC-1295, and ipamorelin are all unapproved for human use by the FDA. The agency's position is clear. In 2022, the FDA clarified that many peptides, including BPC-157, are not eligible for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. BPC-157 specifically appears on the FDA's list of bulk substances that cannot be compounded because they present significant safety concerns or lack sufficient evidence of clinical use. That is a real regulatory red line, not a technicality.

However, some of the evidence base is not nothing. A 2018 review by Chang and colleagues in the journal Current Pharmaceutical Design examined BPC-157's gastroprotective and systemic healing properties primarily in rodent models, finding consistent effects on angiogenesis and tissue repair. The problem is that animal data does not translate automatically to safe human use, and no Phase II or Phase III trials in humans have been completed for most of these compounds.

What did they get wrong (or right)?

She got the regulatory picture right. Calling these peptides "research purposes only" is accurate shorthand for their current legal and scientific status in the United States.

What's oversimplified is the word "scam." A scam implies deliberate fraud with no underlying mechanism. That's not quite right either. Some peptides in this category, like GHK-Cu, have peer-reviewed research exploring wound healing and skin remodeling, including work by Pickart and Margolina published in 2018 in Cosmetics. Others, like ipamorelin, have been studied in clinical contexts for conditions like postoperative ileus, though they never reached broad FDA approval.

The more accurate framing is this: there is preliminary or preclinical evidence for some of these compounds, but the gap between "interesting animal data" and "safe, effective, approved human therapy" is enormous, and that gap is currently being papered over by wellness marketing. Calling it a scam collapses a nuanced regulatory and scientific problem into a one-liner, which is its own form of oversimplification.

What should you actually know?

If you are considering peptide therapy, the regulatory status matters more than the influencer testimonials. Here is what the evidence actually supports:

• The FDA's 2023 guidance explicitly restricted compounding of several popular peptides, including BPC-157 and TB-500, meaning compounding pharmacies in the U.S. are not legally permitted to prepare these for patient use.
• MK-677 (ibutamoren) is not a peptide, it is a small molecule ghrelin mimetic, but it is often marketed alongside peptides. It is also not FDA-approved and has been flagged by the FDA as an unapproved new drug.
• Growth hormone secretagogues like CJC-1295 and ipamorelin stimulate the pituitary gland to release growth hormone. Long-term effects of this stimulation in healthy adults remain unstudied in rigorous human trials.
• The "research use only" label on raw peptide products does not mean they have been tested for purity, sterility, or safe injection. Contamination risk in unregulated supply chains is real and documented.
• If a provider is prescribing these compounds without disclosing their unapproved status or the limits of the evidence, that is a consent and transparency problem, regardless of what you believe about their potential benefits.

The bottom line is that the regulatory and evidentiary gaps are real. The wellness industry has moved faster than the science, and consumers are absorbing the risk of that gap.